Outpatient parenteral antimicrobial therapy (OPAT) using a continuous ambulatory delivery device (CADD) allowing treatment with multiple daily doses: a brief report of a Norwegian experience.

IF 3.7 Q2 INFECTIOUS DISEASES

JAC-Antimicrobial Resistance Pub Date : 2024-10-14 eCollection Date: 2024-10-01 DOI:10.1093/jacamr/dlae155

Vegard Skogen, Rita Helleren, Marianne Giske Jacobsen, Anne Opsal, Frode Gallefoss

{"title":"Outpatient parenteral antimicrobial therapy (OPAT) using a continuous ambulatory delivery device (CADD) allowing treatment with multiple daily doses: a brief report of a Norwegian experience.","authors":"Vegard Skogen, Rita Helleren, Marianne Giske Jacobsen, Anne Opsal, Frode Gallefoss","doi":"10.1093/jacamr/dlae155","DOIUrl":null,"url":null,"abstract":"Background: Outpatient parenteral antimicrobial therapy (OPAT) is safe, effective and increasingly available. While OPAT in Norwegian healthcare has been rare, a new continuous ambulatory delivery device (CADD) allowing multiple daily dosing treatments has been innovated making OPAT more accessible.Objectives: To describe the clinical outcome and safety using CADD in an OPAT setting.Methods: Adult patients in need of parenteral antibiotic treatment were offered OPAT and discharged with a programmable digital infusion pump allowing multiple daily dosings.Results: Altogether, 170 patients were included in the study, among which 21% of all patients (36 of 170) were readmitted to hospital while receiving OPAT or within 30 days after end of intravenous antibiotics. None of the 170 patients died due to OPAT and allergies were not noticeable as a problem.Conclusions: We have developed a safe and clinically effective programme offering OPAT in accordance with Norwegian antibiotic treatment guidelines.","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472154/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Outpatient parenteral antimicrobial therapy (OPAT) is safe, effective and increasingly available. While OPAT in Norwegian healthcare has been rare, a new continuous ambulatory delivery device (CADD) allowing multiple daily dosing treatments has been innovated making OPAT more accessible.

Objectives: To describe the clinical outcome and safety using CADD in an OPAT setting.

Methods: Adult patients in need of parenteral antibiotic treatment were offered OPAT and discharged with a programmable digital infusion pump allowing multiple daily dosings.

Results: Altogether, 170 patients were included in the study, among which 21% of all patients (36 of 170) were readmitted to hospital while receiving OPAT or within 30 days after end of intravenous antibiotics. None of the 170 patients died due to OPAT and allergies were not noticeable as a problem.

Conclusions: We have developed a safe and clinically effective programme offering OPAT in accordance with Norwegian antibiotic treatment guidelines.

查看原文本刊更多论文

使用连续流动给药装置（CADD）进行门诊肠外抗菌治疗（OPAT），允许每日多次给药：挪威经验的简要报告。

背景：门诊病人肠外抗菌疗法（OPAT）安全、有效，而且越来越普及。虽然挪威医疗机构很少使用门诊肠外抗菌疗法，但一种新的连续流动给药装置（CADD）的问世使门诊肠外抗菌疗法更加普及：描述在 OPAT 环境中使用 CADD 的临床效果和安全性：方法：为需要接受肠外抗生素治疗的成人患者提供 OPAT，并使用可编程数字输液泵进行每日多次给药：共有 170 名患者参与研究，其中 21% 的患者（170 人中有 36 人）在接受 OPAT 治疗期间或静脉注射抗生素结束后 30 天内再次入院。170 名患者中没有一人因 OPAT 而死亡，过敏问题也不明显：我们根据挪威抗生素治疗指南制定了一项安全、临床有效的 OPAT 方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAC-Antimicrobial Resistance Multiple-

CiteScore

5.30

自引率

0.00%

发文量

审稿时长

16 weeks